AstraZeneca Cerovive stroke data
This article was originally published in Pharmaceutical Approvals Monthly
AstraZeneca plans to submit its neuroprotectant Cerovive (NXY-059) for disability reduction in patients with acute ischemic stroke in the second half of 2006, the firm says May 4. AZ reported preliminary results of a pivotal trial (SAINT I) in which the free radical trapping agent showed a significant disability reduction versus placebo on the Modified Rankin Scale (p=0.038). However, "on the National Institute of Health Stroke Scale, there was no significant difference" between Cerovive and placebo. "The clinical significance of these findings need to be assessed in light of the outcome" of the ongoing SAINT II and CHANT trials. AstraZeneca is developing Cerovive with Renovis...
You may also be interested in...
COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
Kim Trautman, who authored the US FDA’s Quality System Regulation in the 1990s, tells Medtech Insight that the agency probably won’t release a draft of its updated, harmonized QSR until next year thanks in part to a recent move by HHS secretary Alex Azar to personally sign off on every rule.